Cromos Pharma, where the patients are

R&D Trends

Orphan drug market expected to grow through 2018

Monday, March 24, 2014 02:51 PM

The returns on investment from orphan drugs are expected to help pharma companies overcome the impact of revenue loss due to expiry of patents of blockbuster drugs, according to

More... »

CRF Health eCOA webinar series

Sirtex, Guerbet collaborate on clinical studies in liver cancer

Monday, March 24, 2014 02:50 PM

Sirtex Medical, a global life sciences company, and Guerbet, a pharmaceutical group dedicated to medical imaging worldwide, are collaborating to advance research in primary and secondary metastatic liver cancer. The objective is to evaluate the unmet clinical need in patients with hepatocellular carcinoma, metastatic colorectal cancer, neuroendocrine tumors and a range of other secondary liver cancers.

More... »

Antibacterial drugs market to top $45B globally in 2019

Monday, March 24, 2014 02:48 PM

According to a new market report from Transparency Market Research, a global market intelligence company, the global antibacterial drugs market was valued at $43.55 billion in 2012 and is expected to grow at a CAGR of 0.3% from 2013 to 2019, to reach an estimated value of $45.09 billion in 2019.

More... »

Cord Blood Registry partners with two universities for cerebral palsy innovation

Thursday, March 20, 2014 02:38 PM

Cord Blood Registry (CBR), a newborn stem cell company, is partnering with the University of Texas Health Science Center at Houston and Georgia Regents University to establish FDA-regulated clinical trials investigating whether an intravenous infusion of a child's own cord blood cells, banked at the time of their birth, will lessen the symptoms of cerebral palsy.

More... »

GHIT Fund awards $12M for neglected diseases, launches investment program

Thursday, March 20, 2014 02:22 PM

The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership bringing Japanese experience and investment to the global fight against infectious diseases, has announced three grants worth a total of $6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms.

More... »

Astellas Pharma, Daiichi Sankyo form compound library sharing partnership

Thursday, March 20, 2014 01:07 PM

Astellas Pharma and Daiichi Sankyo will form a compound library sharing partnership for approximately 400,000 selected compounds. The collaboration enables each party to promote innovative new medicine R&D. This is the first time a compound library partnership of this scale has been formed in Japan.

More... »

Industry reacts to U.K. budget announcement

Thursday, March 20, 2014 01:05 PM

Positive and negative industry responses have surfaced regarding Chancellor George Osborne's budget, from the Ethical Medicines Industry Group (EMIG), the BioIndustry Association (BIA) and the Royal College of General Practitioners (RCGP). The budget includes a $90.9 million establishment of a large-scale cell therapy manufacturing center, an increase in the R&D Tax Credit from 11% to 14.5%, and $175.1 million over five years for doctoral training centers.

More... »

Teva, NIHR form health research collaboration

Wednesday, March 19, 2014 12:50 PM

Israeli pharmaceutical company Teva will invest $20 million into U.K. clinical trials and $1 million into U.K. dementia research. Teva said it will benefit from the NIHR's translational research infrastructure and its ability to efficiently set up and deliver world-leading health research studies.

More... »

Sanofi Pasteur, SK Chemical collaborate on pneumococcal conjugate vaccine

Wednesday, March 19, 2014 12:48 PM

Sanofi Pasteur, the vaccines division of Sanofi, has formed a long-term strategic cooperation with SK Chemical to co-develop an innovative pneumococcal conjugate vaccine (PCV). This agreement will enable Sanofi Pasteur to access the global PCV market of $4 billion. The World Health Organization (WHO) recommends the use of PCVs in all countries.

More... »

EffRx Pharmaceuticals, Kadmon form global collaboration

Wednesday, March 19, 2014 12:47 PM

EffRx Pharmaceuticals, a provider of innovative drug delivery technologies that improve efficacy and tolerability of existing compounds, has established a worldwide collaboration with Kadmon, a global biopharmaceutical company, under which EffRx will generate effervescent formulations of products to be developed by Kadmon in both adult and pediatric orphan indications. Financial terms were not disclosed.

More... »

CenterWatch Drugs in Clinical Trials



Browse by:


April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs